Gilead Sciences (NASDAQ:GILD) Given New $95.00 Price Target at Barclays
Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective raised by Barclays from $84.00 to $95.00 in a report issued on Thursday morning,Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company’s stock. Other research analysts have also issued research reports about the company. Sanford C. Bernstein started coverage on […]
More Stories
One Piece Season 2: Release Date, Trailer, Cast, and Other Announcements
One Piece season 2 is expected to be released in 2026, as the shooting was completed in early 2025. For...
Perplexity AI Wants to Buy Google Chrome for $34.5 Billion!
A young artificial intelligence company called Perplexity AI has surprised the tech world by offering $34.5 billion to buy Google...
White House Orders Review of Smithsonian Exhibits Ahead of Nation’s 250th Birthday
By Victoria Friedman The White House on Tuesday ordered an internal review of selected Smithsonian museums and exhibitions to ensure...
Mexico Extradites 26 Alleged Cartel Members to US
By Aldgra Fredly Mexico extradited 26 alleged cartel members to the United States on Aug. 12, including high-ranking members of...
Federal Policing Takes Effect in Washington—What to Know
By Joseph Lord On Aug. 12, National Guard troops arrived in Washington after President Donald Trump federalized policing, citing a...
Chicago Partners Investment Group LLC Sells 837 Shares of Guidewire Software, Inc. (NYSE:GWRE)
Chicago Partners Investment Group LLC decreased its position in shares of Guidewire Software, Inc. (NYSE:GWRE – Free Report) by 42.8%...